<DOC>
	<DOC>NCT01191359</DOC>
	<brief_summary>Multicentre Phase II trial, comparing two different administration routes of SLITonePLUS Birch in regard to pharmacodynamic efficacy and tolerability.</brief_summary>
	<brief_title>Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch</brief_title>
	<detailed_description />
	<criteria>A history of Birch pollen allergy Positive skin prick test to birch Positive specific IgE to birch Exclusion criteria: Uncontrolled or severe asthma (FEV1&lt;70% of predicted value in spite of adequate pharmacologic treatment) Previous treatment by immunotherapy with birch or a crossreactingtree pollen allergen within the previous 5 years Concomitant SLIT with any allergen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>